Horizon Therapeutics price target raised to $90
This was found on "The Fly" July 22:
"Horizon Therapeutics price target raised to $90 from $61 at Piper Sandler 06:03 HZNP Piper Sandler analyst David Amsellem raised the firm's price target on Horizon Therapeutics to $90 from $61 and reiterates an Overweight rating on the shares. The analyst conducted a survey of 25 physicians who are current users of Horizon's Tepezza to gauge the extent to which adoption among physicians who currently use the product in patients with moderate-to-severely active thyroid eye disease will grow over time. The feedback points to "deep penetration" of Tepezza among active thyroid eye disease patients, Amsellem tells investors in a research note. The feedback also points to an "emerging physician audience" in patients with inactive disease, says the analyst. The checks reinforce his view that Tepezza has the makings of a multi-billion dollar franchise."
I think we all know what an analyst target of $90 means. Probably worth $120 to an acquirer. Just my opinion. Smoke 'em if you got 'em. GL longs.